Abby Crites
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abby Crites has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ayo Adeyemi
Global Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Boston, USA
1 shared publication Michelle Erdmann
Global Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Mississauga, Canada
1 shared publication- Phioanh Leia Nghiemphu
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
1 shared publication Rosalie E. Ferner
Neurology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
1 shared publication- Susanna Burckhardt
Global Medical Affairs, Alexion, AstraZeneca Rare Disease, Baar, Switzerland
1 shared publication Theresa Dettling
US Health Economics and Outcomes Research, Alexion, AstraZeneca Rare Disease, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Neurology and Therapy
- p. 1-25
Insights from a Multi-Country Survey: Healthcare Providers’ Perspectives on the Management of Adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma
Introduction Neurofibromatosis type 1 (NF1) is a genetic, multi-system disorder characterized by a range of manifestations. Approximately 50% of patients with NF1 develop peripheral nerve sheath tumors [plexiform neurofibroma (PN)], which can cause substantial morbidity and often progress into adulthood. Historically, NF1-PN research has focused on pediatric patients; however, less is known in adult patients, in whom treatment options are also limited. This study aimed to provide insights into the management and treatment challenges in adults with NF1-PN from the perspective of healthcare providers (HCPs). Methods Two separate studies, one in the US and one across multiple countries (Canada, China, France, Germany, Japan, Italy, Spain, and the UK), were conducted with a mixed-methods, double-blinded design among HCPs who treat adults with NF1-PN. Qualitative interview data were collected to explore survey responses (US) or to inform quantitative study design (multi-country); quantitative data were collected through online surveys. Results Overall, 4 and 16 HCPs participated in the qualitative portion of the US and multi-country studies, whereas 41 and 124 HCPs participated in the quantitative portion, respectively. Physical examinations and radiologic imaging were used for diagnosis of NF1-PN across both studies, but family history was more frequent in the multi-country study (81–83% multi-country; 68–75% US). HCPs reported managing multiple high-burden manifestations, including brainstem or optic gliomas, hearing issues, neurocognitive or visual impairment, and neuropathic pain, resulting in patients missing an average of 6–8 days from school or work per month. Approximately 17–25% of patients drop out of care when transitioning from pediatric to adult care with lack of support/processes/guidelines noted as key challenges. Conclusion These results highlight unmet clinical needs in treatment of adults with NF1-PN worldwide; specifically, limited treatment options for PN growth and symptoms. HCPs identified need for better educational resources for patients and improved transition-of-care processes/resources.
- 8 October 2026
- Published by Springer Nature in Neurology and Therapy
- p. 1-25
Open AccessInsights from a Multi-Country Survey: Healthcare Providers’ Perspectives on the Management of Adults with Neurofibromatosis Type 1 and Plexiform Neurofibroma
Introduction Neurofibromatosis type 1 (NF1) is a genetic, multi-system disorder characterized by a range of manifestations. Approximately 50% of patients with NF1 develop peripheral nerve sheath tumors [plexiform neurofibroma (PN)], which can cause substantial morbidity and often progress into adulthood. Historically, NF1-PN research has focused on pediatric patients; however, less is known in adult patients, in whom treatment options are also limited. This study aimed to provide insights into the management and treatment challenges in adults with NF1-PN from the perspective of healthcare providers (HCPs). Methods Two separate studies, one in the US and one across multiple countries (Canada, China, France, Germany, Japan, Italy, Spain, and the UK), were conducted with a mixed-methods, double-blinded design among HCPs who treat adults with NF1-PN. Qualitative interview data were collected to explore survey responses (US) or to inform quantitative study design (multi-country); quantitative data were collected through online surveys. Results Overall, 4 and 16 HCPs participated in the qualitative portion of the US and multi-country studies, whereas 41 and 124 HCPs participated in the quantitative portion, respectively. Physical examinations and radiologic imaging were used for diagnosis of NF1-PN across both studies, but family history was more frequent in the multi-country study (81–83% multi-country; 68–75% US). HCPs reported managing multiple high-burden manifestations, including brainstem or optic gliomas, hearing issues, neurocognitive or visual impairment, and neuropathic pain, resulting in patients missing an average of 6–8 days from school or work per month. Approximately 17–25% of patients drop out of care when transitioning from pediatric to adult care with lack of support/processes/guidelines noted as key challenges. Conclusion These results highlight unmet clinical needs in treatment of adults with NF1-PN worldwide; specifically, limited treatment options for PN growth and symptoms. HCPs identified need for better educational resources for patients and improved transition-of-care processes/resources.